Santaris Gets $14M From Pfizer

1/4/11Follow @xconomy

Santaris Pharma, the developer of RNA-based therapies in San Diego and Denmark, said today it has expanded its alliance with Pfizer, which has agreed to pay the smaller company $14 million to continue developing its technology. Santaris is also eligible to receive milestone payments of as much as $600 million, and royalties on as many as 10 products Pfizer may develop over time using its RNA technology. The two companies started collaborating in January 2009, when Santaris struck the deal with Wyeth, which has since merged with Pfizer.

By posting a comment, you agree to our terms and conditions.